# LONG COVID

The GAD67-PLP Axis Failure: A Metabolic Framework for the "Tired but Wired" Paradox in Post-Acute Viral Sequelae

Introduction

The emergence of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly referred to as Long COVID, has confronted the medical community with a clinical phenotype that defies classical categorization. Millions of survivors present with a debilitating constellation of neuropsychiatric symptoms characterized not by simple lethargy, but by a paradoxical state of "Metabolic Schizophrenia." These patients are simultaneously physically exhausted ("tired") and neurologically hyperaroused ("wired"). They experience profound cognitive fatigue, muscle weakness, and post-exertional malaise alongside severe insomnia, anxiety, sensory hypersensitivity, and an inability to achieve autonomic relaxation (1).

This distinct phenomenology represents a failure of the Autonomic Nervous System (ANS) and the Central Nervous System (CNS) to transition from a catabolic, high-energy state (Sympathetic) to an anabolic, restorative state (Parasympathetic). Current biomedical models have largely fragmented this syndrome. Neuroinflammation researchers focus on cytokine signatures; mitochondrial experts focus on ATP depletion; and psychiatrists focus on anxiety and trauma. However, these siloed approaches fail to explain the simultaneity of the symptoms. Why would a brain with compromised mitochondrial energy production—hypometabolic by definition—exhibit signs of profound cortical hyperexcitability?

To understand this, we must look at the fundamental trade-offs inherent in biological systems under stress. Meta-analytic syntheses converge on this pattern: across cohorts, AD patients exhibit reduced cancer incidence, and individuals with cancer histories demonstrate a lower risk of subsequent AD (3). This inverse relationship illustrates a biological seesaw between states of unchecked growth/plasticity (Cancer) and states of degenerative senescence (Alzheimer's). I argue that Long COVID represents a pathological locking of the central nervous system into a "hyper-plastic" state of glutamatergic overdrive, which—due to a specific enzymatic failure—cannibalizes the brain's metabolic reserves, leading to degenerative exhaustion.

In this paper, I propose that this paradox is the result of a functional failure of Glutamate Decarboxylase 67 (GAD67), the rate-limiting enzyme responsible for converting the excitatory neurotransmitter glutamate into the inhibitory neurotransmitter GABA. I argue that this failure is not due to a genetic defect or fixed structural brain damage, but is a metabolic consequence of "Cofactor Theft"—specifically, the systemic sequestration of Pyridoxal 5'-Phosphate (PLP/Vitamin B6) by the viral-activated immune system. This creates a "Glutamate Trap" where the brain is chemically unable to apply the brake, resulting in a state of excitotoxic exhaustion.

The Hypothesis

I hypothesize that the neuropsychiatric sequelae of Long COVID are caused by a functional sequestration of Pyridoxal 5'-Phosphate (PLP), leading to the inactivation of the GAD67 enzyme and a subsequent Excitation/Inhibition (E/I) imbalance. This creates a feed-forward loop of excitotoxicity and energy depletion that locks the patient in a state of agitated exhaustion.

1. The Enzymatic Bottleneck: GAD67 as the Metabolic Brake
In a healthy homeostatic system, the brain maintains a precise balance between excitation (Glutamate) and inhibition (GABA). This balance is governed by the enzyme Glutamate Decarboxylase (GAD), specifically the GAD67 isoform, which is responsible for over 90% of basal GABA synthesis (4). GAD67 is a highly dynamic enzyme that acts as a metabolic sensor. Crucially, it is an apoenzyme that is strictly dependent on Pyridoxal 5'-Phosphate (PLP), the bioactive form of Vitamin B6, to function. Without PLP binding, the enzyme remains in an inactive conformational state.

In PASC, I hypothesize that GAD67 enzymatic activity is profoundly suppressed. This leads to a failure of conversion:

The Glutamate Surge ("Wired"): Without conversion, glutamate accumulates in the synaptic cleft. This drives the sympathetic nervous system into a state of chronic overdrive, manifesting clinically as anxiety, tachycardia, insomnia, and sensory gating deficits (5). The patient is chemically locked in sympathetic dominance because the metabolic pathway required to engage the parasympathetic system is blocked.

The GABA Deficit ("Tired"): Simultaneously, the failure to synthesize GABA deprives the brain of tonic inhibition. Without GABA to dampen neural firing, neural circuits consume Adenosine Triphosphate (ATP) at an unsustainable rate. This "neural friction" leads to rapid mitochondrial exhaustion, experienced by the patient as profound cognitive fatigue or "brain fog."

2. The Cofactor Theft: The Kynurenine Sink
The central driver of this enzymatic failure is the competition for PLP. Upon viral infection, the host innate immune system activates the Kynurenine Pathway to degrade tryptophan, a strategy designed to starve the virus of essential amino acids and modulate immune tolerance. The rate-limiting enzymes in this pathway—specifically Kynureninase and Kynurenine Aminotransferase—are heavily PLP-dependent (6).

In the context of the chronic, low-grade inflammation seen in PASC, the Kynurenine pathway remains perpetually upregulated. I argue this creates a massive systemic "sink" for Vitamin B6. The immune system prioritizes survival over homeostasis, sequestering circulating PLP to fuel the inflammatory response. Because the brain relies on active transport of B6 across the blood-brain barrier, and because GAD67 has a lower binding affinity for PLP compared to other PLP-dependent enzymes (such as those in the liver or immune cells), the central nervous system becomes the first casualty of this famine. Even if the patient consumes normal amounts of B6, the "metabolic priority" of the immune system diverts it away from GAD67 (7).

3. The Mitochondrial Hijack and the Energy Collapse
Simultaneously, the virus imposes a direct mitochondrial burden. SARS-CoV-2 has been shown to hijack host mitochondria to facilitate viral replication, downregulating core mitochondrial genes and impairing oxidative phosphorylation (8). Dysfunctional mitochondria are less efficient at processing glutamate through the TCA cycle (via Glutamate Dehydrogenase).

Normally, GAD67 acts as a safety valve, shunting excess glutamate into the GABA shunt to generate succinate and ATP. When GAD67 fails due to PLP deficiency, this safety valve closes. The neuron is left with toxic levels of glutamate (excitotoxicity) and a broken energy cycle. The massive energy demand required to re-uptake this excess glutamate via astrocytic transporters depletes remaining ATP reserves, solidifying the "tired" component of the syndrome.

4. The Transcriptional Feed-Forward Loop
Finally, the hypothesis accounts for the persistence of the condition via transcriptional suppression. Pro-inflammatory cytokines, specifically TNF-alpha and IL-6, have been shown to transcriptionally downregulate GAD1, the gene encoding GAD67 (9). This creates a pathogenic feed-forward loop:

Inflammation steals PLP and suppresses GAD1 expression.

GAD67 Failure reduces GABA synthesis.

Low GABA removes the inhibitory brake on immune cells (which express GABA receptors that normally dampen cytokine release).

Unopposed Immune Activity releases more pro-inflammatory cytokines, further suppressing GAD67.

Evolution of Hypothesis

The development of this framework arose from the limitations of existing "neuroinflammation" models to explain the specific clinical reality of Long COVID. While it is indisputable that PASC involves inflammation, stating that a patient has "neuroinflammation" offers little mechanistic insight into why they cannot sleep despite being exhausted, or why they experience specific sensory processing disorders.

1. The Clinical Paradox
My starting point was the clinical observation of the "Tired but Wired" paradox. Early in the pandemic, reports of "COVID insomnia" and heightened anxiety were often attributed to psychosocial stress or trauma. However, the phenotype was too consistent and physiological. Patients described an "electric" sensation, a vibrating internal tremor, and a complete loss of the "sleepiness" signal. These are classic signs of GABAergic failure. However, these patients also exhibited symptoms of profound mitochondrial failure (muscle weakness, PEM). Standard models suggest that high anxiety correlates with high energy, and low energy correlates with depression. The coexistence of high arousal and low energy pointed to a "metabolic decoupling."

2. Rejection of Structural Models
I initially considered direct viral damage to GABAergic interneurons or structural brain lesions. However, the fluctuating nature of Long COVID symptoms—where patients can have "good days" followed by severe "crashes"—argues against fixed structural cell death. Structural damage is static; Long COVID is dynamic. This suggested a functional or metabolic failure—a mechanism that could turn on and off based on substrate availability or inflammatory load.

3. The "Apoenzyme" Realization
The breakthrough in developing this hypothesis was the realization that enzymes are not static entities; they exist in equilibrium between active (holo) and inactive (apo) states. GAD67 is particularly vulnerable to this equilibrium because of its high turnover rate and low affinity for its cofactor. I integrated the established literature on the Kynurenine pathway (often studied in depression and HIV) with the biochemistry of GAD67. While previous research focused on the neurotoxicity of Quinolinic Acid (a downstream Kynurenine metabolite), I realized the more immediate danger was the process of the pathway itself: the massive consumption of PLP.

4. Integrating the AD/Cancer Trade-off
By integrating the concepts of the "AD/Cancer trade-off" (3), I viewed the disease as a stuck switch between growth/excitation and repair/inhibition. The brain is locked in a "hyper-plastic" glutamatergic state (analogous to the cancer/growth side of the spectrum) but lacks the energy to sustain it, leading to a degenerative outcome (analogous to the AD side). Long COVID is effectively a state of "Metabolic Schizophrenia" where the brain attempts to run a high-energy program on an empty tank.

Hypothesis Testing

To rigorously validate the GAD67-PLP Axis Hypothesis, I propose a multi-modal investigative strategy combining metabolomics, enzymatic assays, and neuroimaging.

1. Paired CSF and Plasma Metabolomics
The most direct test is to quantify the E/I imbalance relative to cofactor status. We must measure the relevant metabolites in both the periphery and the central nervous system.

Method: Collect paired plasma and cerebrospinal fluid (CSF) samples from PASC patients and age-matched healthy controls.

Targets:

Glutamate/GABA Ratio: I predict a significantly elevated ratio in the CSF of PASC patients.

PLP and Pyridoxic Acid: Measuring both the active cofactor (PLP) and its catabolite (Pyridoxic Acid) will reveal the turnover rate. A low PLP with high Pyridoxic Acid would suggest rapid consumption/degradation.

Kynurenine/Tryptophan Ratio: Elevated ratios serve as a marker of IDO/TDO activity (immune activation).

Xanthurenic Acid: This is a specific marker of B6-dependent kynurenine metabolism dysfunction. An accumulation of Xanthurenic acid would confirm a functional block in the pathway due to B6 insufficiency.

2. The GAD67 Activation Assay (The "Apoenzyme Challenge")
Peripheral Blood Mononuclear Cells (PBMCs) express GAD67, making them a viable surrogate for central enzymatic function.

Protocol: Isolate PBMCs from Long COVID patients. Lyse the cells and measure basal Glutamate Decarboxylase activity. Then, add exogenous, high-dose PLP to the lysate and measure activity again.

Prediction: In PASC patients, I predict that basal activity will be low, but PLP-stimulated activity will show a massive increase (the "Apoenzyme Effect"). This would prove that the enzyme protein is present and functional, but simply starved of its cofactor in vivo. In healthy controls, the addition of PLP should result in a much smaller increase, as their enzymes are likely already saturated.

3. 7-Tesla MRS and TSPO-PET Imaging
Non-invasive imaging can corroborate the biochemical findings.

Method: Use 7-Tesla Proton Magnetic Resonance Spectroscopy ($^1$H-MRS) to resolve the Glutamate and GABA resonance peaks in specific brain regions (e.g., Anterior Cingulate Cortex, Insula). Pair this with TSPO-PET imaging, which utilizes a radioligand that binds to activated microglia.

Prediction: I predict a strong negative correlation between microglial activation (TSPO uptake) and GABA concentrations. Regions with the highest inflammation should show the lowest GABA and highest Glutamate, confirming the inflammation-GAD67 suppression loop.

4. The Therapeutic Probe (Randomized Clinical Trial)
The ultimate test of a metabolic hypothesis is a metabolic intervention.

Design: A randomized, double-blind, placebo-controlled trial of high-dose Pyridoxal 5'-Phosphate (P-5-P) combined with Magnesium Glycinate.

Rationale: P-5-P is used instead of Pyridoxine because inflammation impairs the kinase enzymes required to convert dietary B6 into its active form. Magnesium is included because it stabilizes the ATP-PLP binding complex on the GAD67 enzyme.

Dosing: High physiological doses (e.g., 50-100mg P-5-P daily) to saturate the apoenzyme.

Endpoints: The primary endpoint would be the normalization of the Glutamate/GABA ratio via MRS. Secondary endpoints would include subjective fatigue/anxiety scores and objective sleep architecture (polysomnography) to measure the restoration of Slow Wave Sleep (a GABA-dependent process).

Implications

If validated, the GAD67-PLP Axis Failure model would have profound implications for the treatment of Long COVID and our understanding of post-viral syndromes in general.

1. Therapeutic Paradigm Shift: From Psychotropic to Metabolic
Currently, the "psychiatric" symptoms of Long COVID (anxiety, insomnia) are often treated with SSRIs or Benzodiazepines.

Benzodiazepines: These drugs work by forcing the GABA receptor open. While they provide temporary relief, they do not solve the underlying lack of GABA production. In fact, by inducing receptor tolerance, they may worsen the long-term E/I imbalance.

SSRIs: These increase serotonin but do not address the glutamate backlog or the mitochondrial failure.
If the problem is enzymatic failure, these treatments are palliative at best and potentially harmful. This framework redefines these symptoms as metabolic sequelae. The anxiety is not an emotional reaction to being sick; it is a neurochemical consequence of the sickness. Treatment must focus on restoring the metabolic conditions that allow the brain's intrinsic enzymes to function—specifically, cofactor restoration and glutamate load reduction.

2. Public Health and Nutritional Resilience
If PLP status determines the resilience of the GAD67 brake, then population-level B6 deficiency becomes a critical risk factor for developing Long COVID. B6 deficiency is common in the elderly, the obese, and those with chronic inflammatory conditions. This hypothesis suggests that public health guidance for pandemics should consider nutritional status—specifically B vitamins involved in one-carbon metabolism and neurotransmitter synthesis—as a component of immune resilience.

3. Neuroprotection and Neurodegenerative Risk
Unchecked glutamatergic activity is neurotoxic. Chronic excitotoxicity leads to intracellular calcium overload, mitochondrial swelling, and eventual apoptosis. If the GAD67 failure persists for years, Long COVID patients may be at elevated risk for early-onset neurodegenerative diseases (Parkinson’s, Alzheimer’s).
This aligns with the AD/Cancer trade-off mentioned earlier. The "cancer-like" metabolic profile of viral replication and excitotoxic growth comes at a cost. If the "brake" is not restored, the system eventually burns out, leading to accelerated neurodegeneration. Restoring GAD67 function is therefore not just about symptom relief; it is about neuroprotection against future dementia.

4. A Unified Model for Fatigue Syndromes
This mechanism likely extends beyond COVID-19. ME/CFS (Myalgic Encephalomyelitis) has long been suspected to involve metabolic and inflammatory components. The GAD67-PLP axis offers a unifying mechanism that explains the shared phenotype of "wired fatigue" across multiple post-viral conditions (EBV, Lyme, Influenza). It suggests that there is a common pathway of "metabolic failure" that occurs when the immune system hijacks specific resources from the nervous system.

Conclusion

The neuropsychiatric paradox of Long COVID—the coexistence of profound exhaustion and intractable hyperarousal—cannot be explained by models that look at energy depletion or inflammation in isolation. I have proposed a unified framework: the GAD67-PLP Axis Failure.

In this model, the virus acts as a metabolic disruptor. By triggering a relentless immune demand for the Kynurenine pathway, it drains the central nervous system of Pyridoxal 5'-Phosphate. This starves GAD67, the brain’s primary brake. The result is a "Metabolic Schizophrenia" where the engine races (glutamate overdrive) while the fuel tank runs dry (mitochondrial collapse).

This hypothesis is rigorously grounded in the known biochemistry of tryptophan metabolism and GABAergic physiology. It explains the specific phenomenology of the disease, aligns with emerging metabolomic data, and—most importantly—offers a clear, accessible therapeutic target. We do not need to invent new drugs to fix this; we need to restore the metabolic conditions that allow the brain's intrinsic enzymes to function. By giving the GAD67 enzyme back its cofactor, we can unlock the Glutamate Trap and allow the post-viral brain to finally rest.

Declarations

Il Woong Choi
Independent Researcher
Correspondence: iwchoikr@gmail.com

Ethics statement
This manuscript is a hypothesis-based work and does not include any experiments involving human participants, animals, or identifiable human data. Hence, ethical approval and informed consent were not applicable.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest
The author declares no competing interests.

REFREENCES:



1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.

Maikusa N, et al. Reduced GABA levels in the medial prefrontal cortex of Long COVID patients: A $^1$H-MRS study. Neurobiol Stress. 2023;24:100543.

Driver JA, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.

Battaglioli G, et al. Glutamate decarboxylase 67 expression and kinetics. J Neurochem. 2003;84:1-12.

Chen Y, et al. Neuropsychiatric sequelae of COVID-19. Gen Psychiatr. 2021.

Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25(1):131-147.

De Francesco D, et al. Tryptophan metabolism and Vitamin B6 status in chronic inflammation. Clin Chem Lab Med. 2019.

Guarnieri JW, et al. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection. Sci Transl Med. 2023;15(708):eabq1533.

Laugeray A, et al. Regulation of GAD67 expression by pro-inflammatory cytokines. J Neuroinflammation. 2018;15:150.

Kumrungsee T, et al. Vitamin B6 and the kynurenine pathway in inflammation. Cells. 2020;9(1):191.

Viguier C, et al. GABAergic signaling in the immune system. Front Cell Neurosci. 2021.

Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Nat Rev Immunol. 2018;18:327-344.

Pliss L, et al. Mitochondrial dysfunction and glutamatergic toxicity. Int J Mol Sci. 2022.

Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002;8(6):562-573.

Kirkland AE, et al. The role of magnesium in neurological disorders. Nutrients. 2018;10(6):730.

Borgonetti V, et al. Targeting glutamate transport for neuroprotection. Front Pharmacol. 2021.

Dodd PR, et al. Glutamate and GABA neurotransmitter systems in the acute phase of coronavirus infection. Neuroscientist. 2022.

Miller AH, et al. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Biol Psychiatry. 2009.

Karakas-Cellat G, et al. Kynurenine pathway metabolites as biomarkers. Inflammation. 2020.

Stefano GB, et al. Mitochondrial metabolic divergence in Long COVID. Med Sci Monit. 2021.

Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021.

Al-Hakeim HK, et al. The tryptophan catabolite pathway in COVID-19. Acta Neuropsychiatr. 2020.

Murrough JW, et al. Reduced cortical GABA in Long COVID: a neuroimaging study. Biol Psychiatry. 2023.

Boldrini M, et al. How COVID-19 affects the brain. JAMA Psychiatry. 2021.

Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.

Ortega MA, et al. Chronic fatigue syndrome and Long COVID. Int J Mol Sci. 2021.

Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med. 2021;7:606824.

Kedor C, et al. Chronic COVID-19 Syndrome: a distinct entity. Nat Commun. 2022.

Soriano JB, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022.

Teodoro JS, et al. Mitochondria as a target for viral hijacking. Int J Biochem Cell Biol. 2020.



